◀ Back to EGF

EGF — PLA2G4A

Text-mined interactions from Literome

Yang et al., J Membr Biol 2001 : Taken together, EGF stimulates Erk1/2 ; p38 and cPLA2 activity
Huang et al., J Biol Chem 2002 (MAP Kinase Signaling System) : It has been reported that epidermal growth factor (EGF) induces cPLA(2) activation or cPLA(2) expression and subsequent AA release ... Immunoprecipitation experiments showed that EGF induced increased p11 binding to cPLA(2) in a time- and dose dependent manner
Xu et al., J Neurochem 2002 (MAP Kinase Signaling System) : Epidermal growth factor (EGF) also stimulated phosphorylation of ERK1/2 and cPLA2 [ largely through a protein kinase C ( PKC ) -independent pathway ], but EGF did not evoke AA release
Kisslov et al., Biochim Biophys Acta 2012 (Colonic Neoplasms) : EGF caused a rapid activation of cPLA(2)a which coincided with a significant increase in cell proliferation
Adachi et al., Hepatology 1995 : These results suggest that HGF as well as EGF causes AA release, probably through activation of cPLA2 mediated by MAP kinases, and that PGs, metabolites of AA, might play a pivotal role in hepatocyte proliferation in an autocrine mechanism
Schalkwijk et al., Eur J Biochem 1995 : In the present study we demonstrate a rapid transient EGF induced activation of this cPLA2 and an EGF induced increase in phosphorylation of the cPLA2 ... The EGF induced activation of cPLA2 is reversed upon phosphatase treatment showing phosphorylation dependent activation of the cPLA2
Maxwell et al., Biochem J 1993 : Cultured rat mesangial cells were used as a model system to test the effects of EGF and PMA on the regulation of cPLA2 gene expression ... EGF and PMA both produced sustained increases in cPLA2 mRNA levels, with a parallel increase in enzyme activity over time ... Actinomycin D treatment entirely abrogated the effect of EGF on cPLA2 mRNA accumulation
Croxtall et al., Biochem Pharmacol 1996 (Adenocarcinoma) : This concept is supported by the fact that a peptide Lc13-25 ( 10-200 micrograms/mL ), derived from the N-terminus of lipocortin 1, also inhibits activation of cPLA2 by EGF in these cells
Sato et al., Prostaglandins 1997 (Carcinoma, Squamous Cell) : These results suggest that EGF augments the production of PGE2 by increasing not only the activity of cPLA2 but also the production of COX-2 in A431 cells
Cybulsky et al., Kidney Int 1998 (Glomerulonephritis, Membranous) : Unlike complement, activation of cPLA2-wt by epidermal growth factor was dependent on PKC, and was augmented significantly by p42 MAPK
Muthalif et al., Proc Natl Acad Sci U S A 1998 : NE-, Ang II-, and EGF stimulated MAPK and cPLA2 were reduced by inhibitors of cytochrome P450 ( CYP450 ) and lipoxygenase but not by cyclooxygenase